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While an increasing number of younger pa-
tients with longer life-expectancy receive tran-
scatheter aortic valve implantation (TAVI), one 
can assume that patients will outlive their biopros-
theses. Thus, repeat interventions after TAVI are 
expected to rise dramatically. Presented herein 
are two cases of failed transcatheter heart valves 
(THV), treated effectively with transcatheter aortic 
valve-in-valve implantation (TAVI-in-TAVI). 
The first, a 75-year-old woman that presented 
with clinical (exercise-induced dyspnea) and the 
echocardiographic (aortic valve area [AVA] was 
0.75 cm2, AVA index 0.43 cm2/m2, paravalvular regurgi-
tation) symptoms of bioprosthetic valve failure (BVF), 
a Sapien XT 23 mm, which was implanted in 2013. 
Transfemoral TAVI-in-TAVI using the self-expandable 
Portico 23 mm, THV was performed resulting in 
a precise implantation (Fig. 1A). Post-operative echo-
cardiography showed an excellent hemodynamic 
result (AVA 1.62 cm2, AVA index 1.04 cm2/m2, without 
para-prosthetic leak), the patient reported symptom 
improvement and after 7 days was discharged.
The second, a 71-year-old man with clinical 
symptoms (exercise-induced dyspnea) of heart 
failure (NYHA III, ejection fraction 27%) and 
echocardiographically confirmed severe aortic 
regurgitation caused mostly by para-prosthetic 
leak (BVF, CoreValve 29 mm, implanted into the 
bicuspid valve in 2013). The Heart Team decided to 
proceed with transfemoral TAVI-in-TAVI using the 
balloon-expandable Sapien 3 29 mm bioprosthesis 
(Fig. 1B). Optimal implantation was achieved, post-
operative echocardiography showed correct func-
tion of implanted bioprothesis; the para-prosthetic 
leak disappeared and gradient was < 10 mmHg. 
The patient was discharged after 6 days.
Taking into consideration the expanding rec-
ommendations and rapid growth of TAVI it can 
be expected that increasingly more BVFs and 
subsequent TAVI-in-TAVI procedures will occur. 
Hemodynamics with desired low trans-prosthetic 
gradient and possible future coronary access should 
be taken into consideration for optimal clinical 
effect. TAVI-in-TAVI procedures may also carry 
an elevated risk of debris embolizing to the brain, 
however, embolic protection devices can be a po-
tential solution to decrease cerebral embolization 
and the associated neurological complications.
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Figure 1. A. Portico 23 mm (upper and lower edge marked by white arrows) implanted into the failing Sapien XT 
23 mm (marked by black arrow); B. Edwards Sapien 3 29 mm (marked by white arrows) implanted into CoreValve 
29 mm (upper and lower edge marked by black arrows).
